BOLT · Bolt Biotherapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.0K | - | $2.17M | $1.80M | $1.22M | - | $1.14M | $1.27M | $5.27M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $4.83M | - | $6.54M | $7.50M | $9.51M | - | $13.79M | $15.43M | $16.53M | - |
| SG&A | $2.80M | - | $3.34M | $3.52M | $3.83M | - | $3.80M | $4.87M | $5.84M | - |
| Total Operating Expenses | $7.63M | - | $9.87M | $11.01M | $13.34M | - | $17.58M | $23.87M | $22.37M | - |
| D&A | $203.0K | - | $300.0K | $300.0K | $399.0K | - | $500.0K | $400.0K | $458.0K | - |
| Operating Income | ($7.60M) | - | ($7.70M) | ($9.21M) | ($12.12M) | - | ($16.44M) | ($22.60M) | ($17.09M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($7.24M) | - | ($7.14M) | ($8.56M) | ($11.04M) | - | ($15.18M) | ($21.20M) | ($10.81M) | - |
| EPS - Basic | ($4.31) | - | ($3.72) | ($4.46) | ($5.80) | - | ($8.00) | ($11.20) | ($5.60) | - |
| EPS - Diluted | ($4.31) | - | ($3.72) | ($4.46) | ($5.80) | - | ($8.00) | ($11.20) | ($5.60) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $11.61M | $11.70M | $17.75M | $9.60M | $8.39M | $7.21M | $9.37M | $6.20M | $4.26M | $10.81M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.74M | $1.44M | $1.52M | $1.85M | $1.53M | $1.51M | $1.48M | $2.63M | $2.22M | $2.99M |
| Current Assets | $25.75M | $30.26M | $35.61M | $38.34M | $42.51M | $50.81M | $57.15M | $76.63M | $95.06M | $105.71M |
| Total Assets | $48.03M | $56.75M | $65.05M | $75.50M | $85.86M | $99.63M | $109.33M | $124.18M | $142.89M | $159.78M |
| Current Liabilities | $7.34M | $8.44M | $9.97M | $12.31M | $13.56M | $15.86M | $18.08M | $17.90M | $16.72M | $20.46M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $28.20M | $30.24M | $32.95M | $36.66M | $39.05M | $42.43M | $37.30M | $38.32M | $38.73M | $47.04M |
| Stockholders' Equity | $19.82M | $26.50M | $32.10M | $38.84M | $46.81M | $57.20M | $72.03M | $85.86M | $104.16M | $112.74M |
| Retained Earnings | ($468.02M) | ($460.78M) | ($454.15M) | ($447.00M) | ($438.44M) | ($427.40M) | ($411.47M) | ($396.29M) | ($375.10M) | ($364.29M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.02M) | - | - | - | ($13.37M) | - | - | - | ($16.75M) | - |
| Investing Cash Flow | $7.92M | - | - | - | $14.55M | - | - | - | $10.20M | - |
| Financing Cash Flow | $6.0K | - | - | - | $0 | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | $0 | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($16.75M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -29234.6% | - | -355.1% | -510.5% | -991.4% | - | -1441.1% | -1772.3% | -324.1% | - |
| EBITDA margin | -28453.8% | - | -341.3% | -493.9% | -958.8% | - | -1397.3% | -1740.9% | -315.4% | - |
| Net margin | -27861.5% | - | -329.4% | -474.6% | -903.4% | - | -1330.1% | -1662.4% | -205.0% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -317.6% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 1.55 | - |
| R&D / Revenue | 18573.1% | - | 301.3% | 415.6% | 778.4% | - | 1208.2% | 1210.4% | 313.4% | - |
| SG&A / Revenue | 10761.5% | - | 153.8% | 194.9% | 313.0% | - | 333.0% | 382.3% | 110.7% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -15.1% | - | -11.0% | -11.3% | -12.9% | - | -13.9% | -17.1% | -7.6% | - |
| Return on equity | -36.5% | - | -22.3% | -22.0% | -23.6% | - | -21.1% | -24.7% | -10.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.51 | 3.59 | 3.57 | 3.11 | 3.13 | 3.20 | 3.16 | 4.28 | 5.68 | 5.17 |
| Quick ratio | 3.51 | 3.59 | 3.57 | 3.11 | 3.13 | 3.20 | 3.16 | 4.28 | 5.68 | 5.17 |
| Cash ratio | 1.58 | 1.39 | 1.78 | 0.78 | 0.62 | 0.45 | 0.52 | 0.35 | 0.25 | 0.53 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.42 | 2.14 | 2.03 | 1.94 | 1.83 | 1.74 | 1.52 | 1.45 | 1.37 | 1.42 |
| Liabilities / Assets | 0.59 | 0.53 | 0.51 | 0.49 | 0.45 | 0.43 | 0.34 | 0.31 | 0.27 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.03 | 0.02 | 0.01 | - | 0.01 | 0.01 | 0.04 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.3x | - | 0.3x | 0.3x | 6.6x | - | 6.9x | 6.7x | 10.2x | - |
| P / S | 261.1x | - | 4.7x | 6.1x | 251.0x | - | 434.5x | 448.6x | 202.1x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -97.9% | - | 90.1% | 41.5% | -76.8% | - | -54.9% | -11.0% | 188.8% | - |
| Revenue CAGR (3y) | -75.8% | - | 0.9% | 9.0% | 14.5% | - | 14.9% | - | 218.0% | - |
| Revenue CAGR (5y) | -30.8% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 37.3% | - | 53.2% | 59.2% | 29.1% | - | 9.6% | -13.9% | 7.2% | - |
| Net income growth (YoY) | 34.4% | - | 52.9% | 59.6% | -2.1% | - | 6.6% | -17.4% | 36.3% | - |
| EPS growth (YoY) | 25.7% | - | 53.5% | 60.2% | -3.6% | - | -1760.5% | -2233.3% | -1144.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 28.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -57.7% | -53.7% | -55.4% | -54.8% | -55.1% | -49.3% | -43.8% | -39.6% | -33.9% | -34.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Bolt Biotherapeutics against the 5 most active filers in the same SIC group.